174 related articles for article (PubMed ID: 14560561)
1. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology.
de Cremoux P; Coste J; Sastre-Garau X; Thioux M; Bouillac C; Labbé S; Cartier I; Ziol M; Dosda A; Le Galès C; Molinié V; Vacher-Lavenu MC; Cochand-Priollet B; Vielh P; Magdelénat H;
Am J Clin Pathol; 2003 Oct; 120(4):492-9. PubMed ID: 14560561
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
3. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
4. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases.
Knoepp SM; Kuebler DL; Wilbur DC
Diagn Mol Pathol; 2007 Sep; 16(3):125-9. PubMed ID: 17721319
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting.
Carozzi FM; Del Mistro A; Confortini M; Sani C; Puliti D; Trevisan R; De Marco L; Tos AG; Girlando S; Palma PD; Pellegrini A; Schiboni ML; Crucitti P; Pierotti P; Vignato A; Ronco G
Am J Clin Pathol; 2005 Nov; 124(5):716-21. PubMed ID: 16203283
[TBL] [Abstract][Full Text] [Related]
6. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.
Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus detection: verification with cervical cytology.
Matthews-Greer J; Rivette D; Reyes R; Vanderloos CF; Turbat-Herrera EA
Clin Lab Sci; 2004; 17(1):8-11. PubMed ID: 15011974
[TBL] [Abstract][Full Text] [Related]
8. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of reprocessing unsatisfactory cervicovaginal ThinPrep specimens with and without glacial acetic acid: effect on Hybrid Capture II human papillomavirus testing and clinical follow-up.
Agoff SN; Dean T; Nixon BK; Ingalls-Severn K; Rinker L; Grieco VS
Am J Clin Pathol; 2002 Nov; 118(5):727-32. PubMed ID: 12428793
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiology of HPV infection].
Boulanger JC; Sevestre H; Bauville E; Ghighi C; Harlicot JP; Gondry J
Gynecol Obstet Fertil; 2004 Mar; 32(3):218-23. PubMed ID: 15123119
[TBL] [Abstract][Full Text] [Related]
11. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D
Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
13. Anal human papillomavirus testing with Digene's hybrid capture 2 using two different sampling methods.
Roka F; Roka J; Trost A; Schalk H; Zagler C; Kirnbauer R; Salat A
Dis Colon Rectum; 2008 Jan; 51(1):62-6. PubMed ID: 18030530
[TBL] [Abstract][Full Text] [Related]
14. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia.
Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U
J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China.
Zhao FH; Hu SY; Bian JJ; Liu B; Peck RB; Bao YP; Pan QJ; Frappart L; Sellors J; Qiao YL
Cancer Cytopathol; 2011 Dec; 119(6):387-94. PubMed ID: 21774094
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening.
Ekalaksananan T; Pientong C; Sriamporn S; Kongyingyoes B; Pengsa P; Kleebkaow P; Kritpetcharat O; Parkin DM
Gynecol Oncol; 2006 Oct; 103(1):62-6. PubMed ID: 16494930
[TBL] [Abstract][Full Text] [Related]
17. [Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].
Ergünay K; Misirlioğlu M; Firat P; Tuncer ZS; Tuncer S; Yildiz I; Ustaçelebi S
Mikrobiyol Bul; 2008 Apr; 42(2):273-82. PubMed ID: 18697425
[TBL] [Abstract][Full Text] [Related]
18. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
19. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer screening in the early post vaccine era.
Waxman AG
Obstet Gynecol Clin North Am; 2008 Dec; 35(4):537-48; vii. PubMed ID: 19061815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
